Características de pacientes con COVID-19 que usaron corticoides inhalados en el Hospital Regional de Loreto, enero a mayo, 2021

• Autor: López Peña, Alejandro
• Formato: tesis de grado
• Fecha de Publicación: 2022
• Institución: Universidad Nacional De La Amazonía Peruana
• Repositorio: UNAPIquitos-Institucional
• Lenguaje: español
• OAI Identifier: oai:repositorio.unapiquitos.edu.pe:20.500.12737/8312
• Enlace del recurso: https://hdl.handle.net/20.500.12737/8312
• Nivel de acceso: acceso abierto
• Materia: COVID-19; Diagnóstico clínico; Corticoesteroides; Hospitales públicos; https://purl.org/pe-repo/ocde/ford#3.03.08

Objective: To determine the clinical characteristics of patients with COVID-19 who used inhaled corticosteroids at the Regional Hospital of Loreto, January to May, 2021. Methodology and materials: An observational, retrospective, cross-sectional and analytical study of patients hospitalized for COVID-19 from January to May 2021 was carried out. There were 731 medical records, using exclusion criteria, a total of 257 records were obtained, in which it was found two groups of patients: those who used inhaled corticosteroids (ICS) (n=155) and those who did not use ICS (n=102). Sociodemographic data, comorbidities, symptoms, complications and outcome were extracted; these were evaluated using tables of frequency, standard deviation and mean; Chi-square was used to analyze the association of categorical variables, and Mann-Whitney U was used for quantitative variables. Results: The mean age of the patients who used ICs was 56.34 years (IQR: 21–91); mostly male (58.4%), the mean time of illness and hospital stay of those who used ICs was higher by 0.73 (9.23 vs 8.5) and 1.03 (8. 55 vs 7.52) days, respectively, of those who did not use ICs. 60.3% (n=155) used ICs during their hospitalization, with a mean time of use of 3.79 days, of which the majority used less than 7 days (56.8%). Among the most used CIs, Beclomethasone was found in 153 (98.7%), with an average dose of 1380.72 ug/day. The time of illness and hospital stay were significantly associated with the use of ICs. Comorbidities, complications, and mortality were not significantly associated with the use of ICs. Conclusion: The time of illness and hospital stay were significantly associated with the use of ICs. The outcome and the use of ICs were not significantly associated, with which it is concluded that the use of ICs would not influence the mortality of patients with COVID-19 who used ICs.